Cara M. Robertus

This paper develops programmable protein degraders (uAbs) that selectively knock down pathogenic β-catenin in vitro and in vivo, reducing tumor cell survival and proliferation.

This study uses lipid nanoparticles to deliver peptide-based degraders, enabling targeted protein degradation in cancer cells and demonstrating reduced target levels in mice.